9th Commercializing Continuous Processing Summit
The 9th CCP Summit accommodated the modern-day ESG targets for biopharma and a burning desire to uncover more cost-effective drug development applications. This was the only industry meeting with content tailored towards the complete pipeline of therapeutics, with a focus extending beyond technical approach, through to strategic developments.
What Was New for 2025?
Strategic sessions led by senior biopharma leaders to help facilitate your shift from batch to continuous with no questions asked
Elevated content tailored towards biologics and novel modalities to help progress towards seamless continuous processing
Scale-up success stories to help futureproof your small molecule development
Reimagined workshops targeting tech transfer and cross-modal applications, with modality breakout sessions
This was an opportunity to unlock the potential for greener, cost-efficient drug development for your small molecules, biologics, and novel modalities.
Our Delegates Had the Chance To...
Futureproof tech transfer and product quality via process control to maintain patient efficacy
Inspire their strategic business cases for continuous processing to win over their senior management
Better understand continuous processing in the context of emerging cell and gene modalities to explore pipeline potential
Quantify sustainability during continuous processing to better influence green chemistry
Collaborate to inspire modernized continuous processing applications for their therapeutic area
What Your Peers Had to Say
“The topics were well chosen and the presenters were extremely competent.” - Drug Substance Technical & New Technologies Focus Area Lead, Roche
Who Was There?
